| scholarly article | Q13442814 |
| P50 | author | Bo Shan | Q95946168 |
| Mengle Shao | Q37377253 | ||
| P2093 | author name string | Yang Liu | |
| Yong Liu | |||
| Jian Zhou | |||
| Liu Yang | |||
| Yong-liang Zhang | |||
| Shan Jiang | |||
| Zhi Dai | |||
| Wei-ping Jia | |||
| Cheng Yan | |||
| Qi-chen Fang | |||
| Jing-qi Liu | |||
| Hua-ting Li | |||
| Yi-ping Deng | |||
| P2860 | cites work | Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study | Q21135215 |
| XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor | Q24292102 | ||
| Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 | ||
| FGF-21 as a novel metabolic regulator | Q24523933 | ||
| Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State | Q24625976 | ||
| UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. | Q42041480 | ||
| Induction of liver steatosis and lipid droplet formation in ATF6alpha-knockout mice burdened with pharmacological endoplasmic reticulum stress | Q42451739 | ||
| Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride | Q42950501 | ||
| Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice | Q43224118 | ||
| Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. | Q43494872 | ||
| Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice | Q44504595 | ||
| High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China | Q44554249 | ||
| Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease | Q44934521 | ||
| Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. | Q45966977 | ||
| Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects | Q46076306 | ||
| Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice | Q46141813 | ||
| The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. | Q46445480 | ||
| Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans | Q46770146 | ||
| Hepatic IRE1α regulates fasting-induced metabolic adaptive programs through the XBP1s-PPARα axis signalling. | Q51324999 | ||
| Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. | Q51362717 | ||
| Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine | Q63609769 | ||
| Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II | Q81144490 | ||
| Endocrine fibroblast growth factors 15/19 and 21: from feast to famine | Q24629260 | ||
| Endoplasmic reticulum stress and the inflammatory basis of metabolic disease | Q24633352 | ||
| Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family | Q24676527 | ||
| BetaKlotho is required for metabolic activity of fibroblast growth factor 21 | Q24681531 | ||
| The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling | Q27008029 | ||
| Signal integration in the endoplasmic reticulum unfolded protein response | Q27860577 | ||
| The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response | Q27933479 | ||
| The unfolded protein response pathway in Saccharomyces cerevisiae. Oligomerization and trans-phosphorylation of Ire1p (Ern1p) are required for kinase activation | Q27936284 | ||
| Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase | Q27938837 | ||
| Regulated translation initiation controls stress-induced gene expression in mammalian cells | Q28506388 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| Fibroblast growth factor 21 is induced by endoplasmic reticulum stress | Q28581415 | ||
| The unfolded protein response: from stress pathway to homeostatic regulation | Q29547396 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states | Q29615208 | ||
| Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21 | Q29615209 | ||
| The unfolded protein response: controlling cell fate decisions under ER stress and beyond | Q29615499 | ||
| Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus | Q29620179 | ||
| FGF-2 prevents cancer cells from ER stress-mediated apoptosis via enhancing proteasome-mediated Nck degradation | Q30009914 | ||
| Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis | Q34169287 | ||
| Fibroblast growth factor 21 corrects obesity in mice | Q34805555 | ||
| PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism | Q35229188 | ||
| Endoplasmic reticulum stress in liver disease | Q36031838 | ||
| Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines. | Q36846138 | ||
| An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice | Q36886578 | ||
| Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects | Q36971939 | ||
| Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage | Q36982020 | ||
| The role for endoplasmic reticulum stress in diabetes mellitus | Q37019672 | ||
| Non-alcoholic fatty liver disease and the metabolic syndrome: an update | Q37054351 | ||
| Ppp1r15 gene knockout reveals an essential role for translation initiation factor 2 alpha (eIF2alpha) dephosphorylation in mammalian development | Q37100863 | ||
| Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss | Q37105351 | ||
| Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects | Q38351110 | ||
| Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines | Q39800763 | ||
| Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. | Q40895648 | ||
| Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. | Q41760918 | ||
| The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis | Q41904044 | ||
| P433 | issue | 43 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endoplasmic reticulum | Q79927 |
| steatosis | Q1365091 | ||
| P304 | page(s) | 29751-29765 | |
| P577 | publication date | 2014-08-28 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis | |
| P478 | volume | 289 |
| Q38754314 | A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease |
| Q35407627 | A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodelling. |
| Q58697388 | A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis |
| Q55137606 | CREBH Regulates Systemic Glucose and Lipid Metabolism. |
| Q91809334 | Caspase-2 and p75 neurotrophin receptor (p75NTR) are involved in the regulation of SREBP and lipid genes in hepatocyte cells |
| Q45965446 | Clinical and genetic characterisation of infantile liver failure syndrome type 1, due to recessive mutations in LARS. |
| Q91089901 | Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Contributes to Hepatic Steatosis |
| Q45324129 | Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases |
| Q54123115 | Dual role for inositol-requiring enzyme 1α in promoting the development of hepatocellular carcinoma during diet-induced obesity in mice. |
| Q42362670 | Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease |
| Q36646646 | Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease |
| Q89414485 | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study |
| Q38925531 | Endoplasmic reticulum proteostasis in hepatic steatosis. |
| Q97522970 | Endoplasmic reticulum stress and liver diseases |
| Q47239353 | Endoplasmic reticulum stress in the pathogenesis of fibrotic disease |
| Q38287666 | Endotoxemia-mediated activation of acetyltransferase P300 impairs insulin signaling in obesity |
| Q92581837 | Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21 |
| Q35179821 | Expression and clinical significance of fibroblast growth factor 1 in gastric adenocarcinoma |
| Q51189900 | FGF21 Is an Exocrine Pancreas Secretagogue. |
| Q38966510 | FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process |
| Q89669025 | FGF21 and the Physiological Regulation of Macronutrient Preference |
| Q49359562 | FGF21-induced by carbon monoxide mediates metabolic homeostasis via the PERK/ATF4 pathway |
| Q51246528 | Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver. |
| Q36674741 | Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21 |
| Q90224598 | Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges |
| Q38783501 | Fibroblast growth factor 21 induction by activating transcription factor 4 is regulated through three amino acid response elements in its promoter region |
| Q53654532 | Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. |
| Q37137238 | Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. |
| Q38733095 | Fibroblast growth factor 21 reverses suppression of adiponectin expression via inhibiting endoplasmic reticulum stress in adipose tissue of obese mice |
| Q39168770 | Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism |
| Q35086484 | GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment. |
| Q40216244 | Gastric bypass surgery is protective from high-fat diet-induced non-alcoholic fatty liver disease and hepatic endoplasmic reticulum stress |
| Q45052537 | Glucagon and Insulin Cooperatively Stimulate Fibroblast Growth Factor 21 Gene Transcription by Increasing the Expression of Activating Transcription Factor 4. |
| Q37325835 | Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. |
| Q37098973 | Hepatic Aryl Hydrocarbon Receptor Attenuates Fibroblast Growth Factor 21 Expression |
| Q37052937 | Hepatic Fatty Acid Oxidation Restrains Systemic Catabolism during Starvation. |
| Q58616116 | Hepatic Sel1L-Hrd1 ER-associated degradation (ERAD) manages FGF21 levels and systemic metabolism via CREBH |
| Q93035446 | Hepatic nitric oxide synthase 1 adaptor protein regulates glucose homeostasis and hepatic insulin sensitivity in obese mice depending on its PDZ binding domain |
| Q49385649 | Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. |
| Q47428749 | Hepatocyte-specific deletion of BAP31 promotes SREBP1C activation, promotes hepatic lipid accumulation, and worsens IR in mice |
| Q89063903 | Homeostatic sensing of dietary protein restriction: A case for FGF21 |
| Q64999429 | IRE1α prevents hepatic steatosis by processing and promoting the degradation of select microRNAs. |
| Q33561352 | Identification of Sp1 as a Transcription Activator to Regulate Fibroblast Growth Factor 21 Gene Expression. |
| Q57797975 | Increased FGF21 in brown adipose tissue of tyrosine hydroxylase heterozygous mice: implications for cold adaptation |
| Q38816036 | Increased lipogenesis in spite of upregulated hepatic 5'AMP-activated protein kinase in human non-alcoholic fatty liver |
| Q47104419 | Induction of fibroblast growth factor 21 does not require activation of the hepatic X-box binding protein 1 in mice |
| Q89533265 | Inhibitory mechanism of muscone in liver cancer involves the induction of apoptosis and autophagy |
| Q87753980 | Interaction between stress responses and circadian metabolism in metabolic disease |
| Q28066564 | Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines |
| Q58773148 | Muscle Loss in Chronic Liver Diseases: The Example of Nonalcoholic Liver Disease |
| Q38705659 | Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies |
| Q37670086 | Nuclear Receptors Resolve Endoplasmic Reticulum Stress to Improve Hepatic Insulin Resistance |
| Q58783695 | PGC-1α in hepatic UPR during high-fat high-fructose diet and exercise training in mice |
| Q28822090 | Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity |
| Q26781431 | Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD |
| Q35613153 | Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet |
| Q38811934 | Targeting endoplasmic reticulum stress in liver disease. |
| Q37726145 | The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms |
| Q58778511 | The IRE1α-XBP1s pathway promotes insulin-stimulated glucose uptake in adipocytes by increasing PPARγ activity |
| Q54201958 | The assembly of lipid droplets and their roles in challenged cells. |
| Q47611637 | The eIF2-alpha kinase HRI: a potential target beyond the red blood cell |
| Q51726693 | Upregulation of rat liver PPARα-FGF21 signaling by a docosahexaenoic acid and thyroid hormone combined protocol. |
| Q28542460 | Whole genome transcript profiling of drug induced steatosis in rats reveals a gene signature predictive of outcome |
| Q55034032 | XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression. |
| Q36610832 | β-aminoisobutyric acid attenuates hepatic endoplasmic reticulum stress and glucose/lipid metabolic disturbance in mice with type 2 diabetes |
Search more.